Bolt Biotherapeutics Files 2024 10-K
Ticker: BOLT · Form: 10-K · Filed: Mar 24, 2025 · CIK: 1641281
| Field | Detail |
|---|---|
| Company | Bolt Biotherapeutics, Inc. (BOLT) |
| Form Type | 10-K |
| Filed Date | Mar 24, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, pharmaceuticals, financials
TL;DR
Bolt Bio's 2024 10-K is in. Check out their Innovent & Genmab deals.
AI Summary
Bolt Biotherapeutics, Inc. filed its 2024 10-K on March 24, 2025, reporting on its fiscal year ending December 31, 2024. The company, previously known as Bolt Therapeutics, Inc., is in the pharmaceutical preparations industry. Key agreements mentioned include the Innovent Agreement and the Genmab Agreement, with financial data related to fair value measurements and common stock.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Bolt Biotherapeutics' financial health, operational activities, and strategic agreements for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a company in the pharmaceutical preparations industry, Bolt Biotherapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2834 — SIC Code (Pharmaceutical Preparations industry)
- 001-39988 — SEC File Number (Company's SEC filing identifier)
Key Players & Entities
- Bolt Biotherapeutics, Inc. (company) — Filer
- 2024-12-31 (date) — Fiscal Year End
- 2025-03-24 (date) — Filing Date
- Bolt Therapeutics, Inc. (company) — Former Company Name
- Innovent Agreement (agreement) — Key Agreement
- Genmab Agreement (agreement) — Key Agreement
FAQ
What is the primary business of Bolt Biotherapeutics, Inc.?
Bolt Biotherapeutics, Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code 2834.
When did Bolt Biotherapeutics, Inc. file its 10-K report for the fiscal year 2024?
The 10-K report for the fiscal year ending December 31, 2024, was filed on March 24, 2025.
What were some of the significant agreements mentioned in the filing?
The filing mentions the 'Innovent Agreement' and the 'Genmab Agreement'.
What was the former name of Bolt Biotherapeutics, Inc.?
The former name of Bolt Biotherapeutics, Inc. was Bolt Therapeutics, Inc., with a name change date of May 4, 2015.
What is the company's principal business address?
The company's principal business address is 900 Chesapeake Drive, Redwood City, CA 94063.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 24, 2025 regarding Bolt Biotherapeutics, Inc. (BOLT).